{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:23Z","timestamp":1790996543224,"version":"4.1.0"},"reference-count":171,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/14740338.2023.2227096","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T11:02:22Z","timestamp":1688468542000},"page":"563-579","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson\u2019s disease"],"prefix":"10.1080","volume":"22","author":[{"given":"Angela M","family":"Richmond","sequence":"first","affiliation":[{"name":"Parkinson\u2019s and Movement Disorders Division, Department of Neurology, The University of Kansas Medical Center, Kansas, KS, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E","family":"Lyons","sequence":"additional","affiliation":[{"name":"Research and Education, Parkinson\u2019s and Movement Disorders Division, Department of Neurology, The University of Kansas Medical Center, Kansas, KS, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"Laverne & Joyce Rider Professor of Neurology, Chief, Parkinson\u2019s and Movement Disorders Division Director, Parkinson\u2019s Foundation Center of Excellence, The University of Kansas Medical Center, Kansas, KS, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"cit0001","first-page":"787","volume":"73","author":"Birkmayer W","journal-title":"Wien Klin Wochenschr"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20459"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200203000-00006"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1057"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.06.005"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.suppl_1.S51"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.02.001"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26125"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5728-8"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70218-0"},{"key":"cit0012","unstructured":"SINEMET\u00ae (Carbidopa-Levodopa) Tablets [prescribing information]. Princeton, NJ: Merck & Co., Inc. 2014. [cited 2023 Feb 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/017555s069lbl.pdf"},{"key":"cit0013","unstructured":"DHIVY (carbidopa and levodopa) tablets [prescribing information]. Washington, DC: Riverside Pharmacy Corporation. 2021. [cited 2023 Mar 21]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214869s000lbl.pdf"},{"key":"cit0014","unstructured":"PARCOPA TM (carbidopa-levodopa orally disintegrating tablets) [prescribing information]. Eden Prairie, MN: Schwarz Pharma. 2007. [cited 2023 Feb 6]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/076699_S000_PARCOPA_PRNTLBL.pdf"},{"key":"cit0015","unstructured":"SINEMET\u00ae CR (carbidopa levodopa) Sustained-Release Tablets [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc. 2014. [cited 2023 Feb 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019856s016s024s028lbl.pdf"},{"key":"cit0016","unstructured":"DUOPA\u00ae(carbidopa and levodopa) enteral suspension [prescribing information]. North Chicago, IL: AbbVie Inc. 2022. [cited 2023 Feb 6]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/203952s004lbl.pdf"},{"key":"cit0017","unstructured":"Rytary (carbidopa and levodopa) extended-release capsules [prescribing information]. Hayward, CA: Impax Pharmaceuticals. 2019. [cited 2023 Feb 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/203312s000lbl.pdf"},{"key":"cit0018","unstructured":"INBRIJA\u2122 (levodopa inhalation powder) [prescribing information]. Ardsley, NY: Acorda Therapeutics, Inc. 2022. [cited 2023 Feb 6]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209184s000lbl.pdf"},{"issue":"3","key":"cit0019","first-page":"188","volume":"121","author":"Markham CH","year":"1974","journal-title":"West J Med"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1159\/000117399"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23158"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70025-5"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.08.017"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26611"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2016.1354"},{"issue":"15","key":"cit0026","volume":"90","author":"Grosset D","year":"2018","journal-title":"Neurology"},{"issue":"15","key":"cit0027","volume":"90","author":"Grosset D","year":"2018","journal-title":"Neurology"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30405-8"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12783"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27338"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100161"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00435-8"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.162"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199508000-00006"},{"key":"cit0036","first-page":"225","volume":"45","author":"Molho ES","year":"1995","journal-title":"J Neural Transm Suppl"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1060"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.4.436"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10508"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20397"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70108-4"},{"issue":"7","key":"cit0042","first-page":"CD007166","volume":"7","author":"Stowe R","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822affdb"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12375"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03822.x"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258660.74391.c1"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000259516.61938.bb"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.9.1385"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30396-5"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20036"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4467"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25751"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1066"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420511"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.4.421"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5.1309"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25418"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4703"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00336-1"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27131"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21315"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212672"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22095"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198802000-00004"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23107"},{"key":"cit0069","unstructured":"MIRAPEX\u00ae (pramipexole dihydrochloride) tablets: Boehringer Ingelheim Pharmaceuticals, Inc; 2018 [February 26, 2023]; Prescribing Information]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020667s036lbl.pdf"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-003-0059-x"},{"issue":"3","key":"cit0071","first-page":"141","volume":"21","author":"Piercey MF","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.65.2_suppl_1.S6"},{"key":"cit0073","unstructured":"MIRAPEX ER\u00ae (pramipexole dihydrochloride) extended-release tablets: Boehringer Ingelheim Pharmaceuticals, Inc; 2018 [February 24, 2023]; Prescribing Information]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022421s017lbl.pdf"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.10.018"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1130128"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70225-X"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30004-2"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12239"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1_Suppl_1.S58"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.393"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619030-00005"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1007\/s007020200040"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-0937-z"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21313"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2016-0038"},{"key":"cit0087","unstructured":"REQUIP XL (ropinirole) extended-release tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2021. [cited 2023 Feb 24]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022008s003s004s007s008lbledt.pdf"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318176c505"},{"key":"cit0089","unstructured":"REQUIP\u00ae (ropinirole hydrochloride) Tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2007. [cited 2023 Feb 23]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020658s018s020s021lbl.pdf"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.65"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12988"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-008-0341-4"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-012-0925-5"},{"key":"cit0094","unstructured":"NEUPRO (rotigotine transdermal system) [prescribing information]. Smyrna, GA: UCB, Inc. 2021. [cited 2023 Feb 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021829s001lbl.pdf"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-019-00682-9"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519110-00006"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.12.1452"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421110-00001"},{"key":"cit0099","unstructured":"Clinical Review Report: Apomorphine (Movapo):Paladin Labs, Inc. Indication: The acute, intermittent treatment of hypomobility \u201coff\u201d episodes (\u201cend-of-dose wearing off\u201d and unpredictable \u201con\/off\u201d episodes) in patients with advanced Parkinson\u2019s disease. Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health; 2018."},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.06.012"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.03.013"},{"key":"cit0102","unstructured":"APOKYN\u00ae (apomorphine hydrochloride injection) [prescribing information]. Louisville, KY: US WorldMeds, LLC; 2016. Accessed 27 February 2023. : https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021264s014lbl.pdf"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100174"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.01.001"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.08.010"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.04.008"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.1.101"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.12.1440"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26697"},{"key":"cit0110","unstructured":"KYNMOBI TM (apomorphine hydrochloride) sublingual film [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2022. Accessed 27 February 2023.: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/210875Orig1s000lbl.pdf"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0249-8"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-022-02465-w"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-019-02082-0"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10191"},{"key":"cit0115","unstructured":"Eldepryl (Selegiline Hydrochloride) [prescribing information]. Tampa, FL: Somerset Pharmaceuticals, Inc; 2008. Accessed 30 January 2023. : https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020647s006s007lbl.pdf"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198713030-00002"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.5.6.705"},{"key":"cit0118","unstructured":"ZELAPAR\u00ae (Selegiline hydrochloride) orally disintegrating tablets [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; 2021. Accessed 30 January 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021479s010lbl.pdf"},{"key":"cit0119","unstructured":"AZILECT\u00ae (rasagiline mesylate) Tablets [prescribing information]. Kansas City, MO: Teva Neuroscience, Inc.; 2003. Accessed 10 February 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021641s002s003s004s005s007s008s010lbl.pdf"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.14.1295.43156"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0408-1"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1007\/BF03033378"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1007\/BF02740748"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150700"},{"key":"cit0125","unstructured":"XADAGO (safinamide) tablets [prescribing information]. Louisville, KY: US WorldMeds, LLC; 2021. Accessed 10 February 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207145lbl.pdf"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25961"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v71i3.2586"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.52965\/001c.39576"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5_Suppl_5.S3"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03081-x"},{"key":"cit0131","unstructured":"TASMAR\u00ae (tolcapone) tablets [prescribing information]. Cost Mesa, CA: Valeant Pharmaceuticals International; 2006. Accessed 28 January 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020697s012lbl.pdf"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199712000-00005"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00888-9"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.2.263"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e318038d2b6"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1159\/000479555"},{"key":"cit0137","unstructured":"COMTAN\u00ae (entacapone) Tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2010. Accessed 28 January 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020796s15lbl.pdf"},{"key":"cit0138","unstructured":"Stalevo\u00ae (carbidopa, levodopa and entacapone) Tablets [prescribing information]. East Hanover, NJ: Novartis Pharmacy Corporation. 2010. [cited 2023 Mar 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021485s20lbl.pdf"},{"key":"cit0139","unstructured":"Ongentys (opicapone) capusles [prescribing information]. San Diego, CA: Neurocrine Biosciences, Inc; 2020. [cited 2023 Jan 30]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212489s000lbl.pdf"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1602-9"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1433659"},{"key":"cit0142","first-page":"703","volume":"161","author":"Jackson GG","year":"1963","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"cit0143","doi-asserted-by":"publisher","DOI":"10.1002\/cpt19667138"},{"key":"cit0144","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1968.03140130001001"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160070046011"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08520-3"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00249-0"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-021-02306-2"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.7.603"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003468"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.24.8.715"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(91)90113-V"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90384-1"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1383"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00004"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I"},{"key":"cit0157","unstructured":"SYMMETREL\u00ae (Amantadine Hydrochloride, USP) Tablets and Syrup [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals, Inc., 2002. [cited 2023 Jan 23]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/016023_S037_SYMMETREL%20SYRUP%20AND%20TABLETS_PRNTLBL.pdf"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814010-00003"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-4-454"},{"key":"cit0160","unstructured":"GOCOVRI TM (amantadine) extended release capsules [prescribing information]. Emeryville, CA: Adamas Pharma LLC; 2021. [cited 2023 Jan 23]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208944lbl.pdf"},{"key":"cit0161","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0663-4"},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-019-0144-1"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(72)90171-3"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197213128"},{"issue":"8","key":"cit0165","first-page":"605","volume":"38","author":"Savery F","year":"1977","journal-title":"Dis Nerv Syst"},{"key":"cit0166","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17622"},{"key":"cit0167","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.03.003"},{"key":"cit0168","doi-asserted-by":"publisher","DOI":"10.1124\/mol.112.084509"},{"key":"cit0169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.08.024"},{"key":"cit0170","unstructured":"NOURIANZ\u2122 (istradefylline) tablets [prescribing information]. Bedminster, NJ: Kyowa Kirin, Inc.; 2020. [cited 2023 Jan 20]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022075s000lbl.pdf"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1003"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2227096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:30:31Z","timestamp":1690183831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2227096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":171,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/14740338.2023.2227096"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2227096","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}